

## Product datasheet for SR300418

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **BCL9 Human siRNA Oligo Duplex (Locus ID 607)**

## **Product data:**

**Product Type:** siRNA Oligo Duplexes

**HPLC** purified **Purity:** 

**Quality Control:** Tested by ESI-MS

Available with shipment **Sequences:** 

Stability: One year from date of shipment when stored at -20°C.

# of transfections: Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final

conc. 10 nM).

Single siRNA duplex (10nmol) can be ordered. Note:

RefSeq: NM 004326

**UniProt ID:** O00512

Synonyms: LGS

Components: BCL9 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 607)

Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol

Included - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml

BCL9 is associated with B-cell acute lymphoblastic leukemia. It may be a target of **Summary:** 

> translocation in B-cell malignancies with abnormalities of 1q21. Its function is unknown. The overexpression of BCL9 may be of pathogenic significance in B-cell malignancies. [provided

by RefSeq, Jul 2008]

**Performance** OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will **Guaranteed:** 

provide at least 70% or more knockdown of the target mRNA when used at 10 nM

concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT

positive control (cat# SR30003) provides 90% knockdown efficiency.

For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data

required).

